In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer

Yi Pang Lee, Che Wei Wang, Wan Chun Liao, Chiung Ru Yang, Chi Tai Yeh, Chung Hung Tsai, Chi Chiang Yang, Yew Min Tzeng

Research output: Contribution to journalArticle

13 Citations (Scopus)


Aim: The study of the anticancer effects of destruxin B (DB) is rare and its anticancer mechanism remains unknown. The aim of this study was to test the in vitro and in vivo anticancer effects of DB, on human HT-29 colorectal cancer (CRC). Materials and Methods: DB was isolated and characterized by high pressure liquid chromatography, electrospray ionization mass spectrometry and 1H- nuclear magnetic resonance spectroscopy. (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay was used to assess the effects of DB on HT-29 cells in vitro. The anticancer effects of DB were investigated in a murine xenograft model of human colon cancer. Results: A significant inhibition of cell viability was observed with DB treatment in time- and dose-dependent manners. DB administered subcutaneously daily at 0.6-15 mg/kg was proven to be safe and effective in inhibiting the growth of CRC cells. Expression of Bax, cleaved poly (ADP-ribose) polymerase and active caspase-3 were observed with DB treatment and the increase in tumor volumes of treated groups were significantly (p

Original languageEnglish
Pages (from-to)2735-2746
Number of pages12
JournalAnticancer Research
Issue number7
Publication statusPublished - Jul 2012



  • 5-FU
  • Colorectal cancer
  • Destruxin B
  • HT-29 cells
  • Xenograft model

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lee, Y. P., Wang, C. W., Liao, W. C., Yang, C. R., Yeh, C. T., Tsai, C. H., Yang, C. C., & Tzeng, Y. M. (2012). In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer. Anticancer Research, 32(7), 2735-2746.